Summary The monoclonal antibody Y13 259 to the ras oncogene protein product p21 was used in an immunohistochemical study of ras expression in human colorectal neoplasms. The ability of the antibody to detect enhanced levels of ras expression was confirmed by its use with an experimental neoplasm known to express ras at high levels. Human colonic adenocarcinomas in general showed a similar staining intensity to that seen in normal mucosa. Adenomas however showed consistently high p21 expression as indicated by staining intensity. This suggests that elevated ras expression may be important in the development of adenomas, but that high levels need not be sustained in the conversion to invasive carcinoma.
Although the ras gene family has been studied longer than any other group of cellular oncogenes, there is still uncertainty over its role in authentic human carcinogenesis. Ras genes code for GTPbinding and GTP'ase enzyme activities of molecular weight 21,000 daltons, referred to as p21 (Shih et al., 1979; Gibbs et al., 1984; McGrath et al., 1984; Sweet et al., 1984) , which appear to be located on the inner face of the plasma membrane (Willingham et al., 1980) , and are probably normally involved in the transduction of membrane-associated stimuli for cell proliferation (Bishop, 1983; . Activation of the genes by mutation has been detected in approximately 15% of a wide variety of spontaneous human tumours and transformed cell lines in culture (Der et al., 1982; Parada et al., 1982; Pulciani et al., 1982; Varmus, 1984) . Raised levels of ras transcript have also been identified in RNA extracted from several types of human tumour (Spandidos & Kerr, 1984; Slamon et al., 1984; Spandidos & Agnantis, 1984; Spandidos et al., 1985) . Controversy remains, however, over whether ras activation is a primary event in carcinogenesis or appears during tumour progression. At a more pragmatic level, it is quite obscure whether the detection of ras expression in pre-malignant lesions or malignant tumours would provide useful diagnostic or prognostic information.
In this paper, we describe the use of the monoclonal antibody Y13 259 in detection of ras p21 in human colorectal neoplasms. We have confirmed the ability of the antibody to detect enhanced levels of ras expression by applying it in parallel to the experimental neoplasm FHO5TI, in which high levels of ras were achieved through genetic manipulation.
Materials and methods

Tissues
Tissues used included 21 adenocarcinomas of the colon and rectum, 6 benign tubular adenomas of the colon, and 7 specimens of colonic tissue resected for non-neoplastic conditions (diverticular disease or ulcerative colitis). The diagnosis in each case was confirmed on paraffin sections. Specimens were received fresh within minutes of resection in the operating theatre. They were examined immediately, samples of tissue taken (including where possible the tumour/normal interface), placed in plastic vials and 'snap' frozen in liquid nitrogen where they were stored until required. Frozen sections (6 pm) were cut, mounted on gelatinecoated slides, fixed in acetone at room temperature for 15 min and air dried. As controls for immunostaining, two cell lines were maintained in culture as previously described (Spandidos & Wilkie, 1984) 
Antibodies
The monoclonal antibody to p21 designated Y13 259 was prepared from the hybridoma cell lines as previously described Preliminary work comparing the indirect, PAP and streptavidin-biotin methods showed highest sensitivity with the latter method. In our hands, the staining shown with Y13 259 in human tissues is generally of relatively low intensity, and it is thus important to minimise non-specific background staining. The clear backgrounds and higher dilutions of primary antibody afforded by the amplified streptavidin-biotin method determined the choice of this method in the main study.
Results
Experimental neoplasm
The transformed cell line FHO5T1 showed strong reactivity of all cells with Y13 259, both in cytocentrifuge preparations and in frozen sections of cell pellets. In contrast, the great majority of cells of the parental strain from which it was derived (untransformed Chinese hamster lung fibroblasts, termed CHL), showed no reactivity. A small proportion however, approximately 5%, showed strong specific staining (Figures 1 and 2 ).
FHO5T1 cells inoculated into nude mice produced malignant tumours of fibrosarcomatous appearance (to be described in detail elsewhere). Frozen sections of such tumours showed strong specific staining of all tumour cells with Y13 259, whilst the adjacent murine tissues were negative (Figure 3) .
The reactivity of Y13 259 with this tumour was completely lost in formalin-fixed paraffin-embedded sections, and was not restored in any measure by trypsinisation. Similarly, formaldehyde or glutaraldehyde fixation of cytocentrifuge preparations of the FHO5T1 cell line abolished antibody binding. Y13 259 is therefore not suitable for use with routinely processed biopsy material.
Human colonic tissues
Positive staining of the intensity of the FHO5T1 tumour was not seen in any of the human colonic tissues studied. In general, where positive staining was detected, it was of low intensity, despite use of the most sensitive peroxidase detection system available to us.
The results of staining of 21 colo-rectal adenocarcinomas, 6 colonic adenomas, their adjacent uninvolved mucosa where available and 7 cases of colonic resections for non-neoplastic conditions are shown in Table I . Staining of sections was independently assessed by two observers and graded as equivocal or negative (+/-); moderate Normal colonic mucosa showed equivocal or faintly positive reactivity of uniform distribution with Y13 259 (Figure 4 ). No significant difference was observed in the mucosa adjacent to neoplastic lesions compared with mucosa from non-neoplastic resections. Adenocarcinomas showed a variable staining pattern; in 15, staining was absent or equivocal, whilst 4 showed moderately strong staining and 2 were graded as intense ( Figure 5 ).
There was no correlation with the histological pattern, depth of invasion or clinical stage of the tumour. Where a difference was observed in staining pattern between the carcinomas and the adjacent mucosa, a sharp transition was not observed. In contrast, 5 out of 6 colonic adenomas showed intensely positive staining ( Figure 6 ). The interface between normal and neoplastic epithelium in the adenomatous lesions did not show a sharp transition in reactivity; positive staining was often most intense at the centre of the adenomas.
Discussion
The monoclonal antibody Y13 259 is one of a series produced in rats bearing tumours induced by the Harvey murine sarcoma virus . These authors showed it to precipitate p21 protein species encoded by both the Harvey and Kirsten strains of the virus. Ther?e is close homology of the protein products of viral and cellular ras genes. Capon et al. (1983a) have shown the viral and cellular p21 protein products to be identical in all but three out of 189 amino acid residues. Y13 259, traced on immunoblots by the streptavidin-biotin method, binds to a single protein band, with an apparent mol.wt of 21,000 on SDS-PAGE, present in substantial quantities in rastransformed cells, and at much lower levels in It was of great value in this study to have access to a known positive control in the form of the experimental neoplasm FHO5T1. This transformed cell line is known to express the mutated T24 Haras oncogene at high levels; quantitation of oncogene mRNA in dot blots indicated 20-60 fold more Ha-ras message in the transformed cells relative to the untransformed parental fibroblasts (Spandidos & Wilkie, 1984) . Whilst there is no formal proof of the specificity of Y13 259 for ras p21, we have established its greatly increased reactivity with ras-transformed cells over their untransformed parental cell strain.
Although increased transcription of activated ras genes has been observed in certain neoplasms (DeFeo et al., 1981; Chang et al., 1982; McCoy et al., 1983) , mutation at specific positions (12 or 61) in the amino acid coding sequence is the feature most consistently observed in ras activation (Capon et al., 1983a; b) . It was therefore not surprising to find that p21 expression in human tumours never attained the artificially high levels seen in the experimental tumour.
The presence of a subpopulation of CHL cells strongly positive with Y13 259 may be related to differential expression of ras at different stages in the cell cycle (Campisi et al., 1984) . It is less likely to represent contamination of CHL by FHO5T1 or spontaneous transformation of CHL cells, as the proportion of ras positive CHL cells has not changed after further passage in continuous culture.
The principal result of this study is the consistently high level of p21 expression in adenomas, whereas the carcinomas in general showed lower staining intensity. As the great majority of colo-rectal carcinomas are believed to arise from adenomatous polyps (Morson & Dawson, 1979) , it would seem that the elevated p21 expression diminishes significantly as the lesions evolve into invasive carcinomas.
An essentially similar conclusion was reached by Spandidos and Kerr (1984) , who reported increased levels of RNA transcripts of Ki-ras and Ha-ras oncogenes in a series of colonic adenomas and adenocarcinomas, but noted higher expression of ras mRNA in some adenomas compared with corresponding carcinomas from the same patients. A recent study employing the same antibody Y13 259 with immunoblotting techniques (Gallick et al., 1985) also reached the conclusion that p21 expression tended to be greatest in the earlier stages of colonic carcinomas.
The p21 proteins are thought to function as transducers of signals from the extracellular environment to the nucleus in a system intimately involved in the control of cellular proliferation (Hurley et al., 1984; Kamata and Feramisco, 1984) . Activation, even by mutation, of ras appears to result in the delivery of a continuous signal rather than a regulated one (Sweet et al., 1984) . Ras activation may be an early event in the development of adenomas, which are known to show a shorter cell cycle time as well as expansion of the proliferating compartment relative to the normal mucosa (Bleiberg & Galand, 1976; Deschner & Lipkin, 1976) . Indeed, cycle times in adenomas are shorter than those of carcinomas. A further carcinogenic stimulus or stimuli may be required for conversion of adenomas to invasive carcinomas, with sustained elevations of ras expression perhaps being no longer necessary. An analogous situation of early ras activation has been described in the context of chemical skin carcinogenesis in mice, where c-Ha-ras has been found to be activated at the stage of benign papilloma formation (Balmain et al., 1984) .
The findings of this study differ significantly from those described by Thor et al. (1984) , who found ras p21 expression to correlate with the depth of invasion of colonic carcinoma within the bowel wall. Using different monoclonal antibodies raised to synthetic peptides reflecting part of the p21 protein structure, they found p21 expression in normal colonic mucosa and colonic adenomas to be negative or very low, whilst carcinomas expressed relatively high levels. This was interpreted as indicating ras activation to be a late stage in the development of colonic malignancy. The reasons for this discrepancy are not clear, but the different methods used in raising these antibodies suggest they may have very different specificities from Y13 259.
It would be of great interest to determine whether the elevated p21 expression detected in adenomas is a product of the normal cellular oncogene, or of the activated mutated gene. The monoclonal antibodies currently available are unable to distinguish between the mutated p21 protein and the normal, but analysis of restriction fragment polymorphism of DNA extracted from tumours may be a more promising approach. Work is currently proceeding in our laboratory to address this question.
